Advanced analytics

FarrSight®-Twin

Predict drug efficacy in pre-clinical models & in individual patients using astrophysics-grade Bayesian AI

Research & Development

Use molecular data from in-vitro models and cancer biopsies to identify biomarkers for solo and combination treatments, accelerate IND submission, and discover novel treatment strategies

Clinical Trials

Integrate spatial and bulk molecular data to create "digital twins" of patients for synthetic controls and  in silico clinical trial simulation to improve probability of drug success through accurate patient selection

Treatment Insights

Plug-in genomic and clinical data to identify more effective and versatile biomarkers for any therapeutic or expand indications and synergistic combinations of a drug asset

Use case

NCT06409221: Clinical trial assessing FarrSight®-Twin in triple-negative breast cancer

Use case

NCT04750109: Patient-level FarrSight®-Twin predictions using tissue and liquid diagnostics in cancer of unknown primary

Use case

Helping pharma with indication expansion for a best-in-class inhibitor

Use case

Simulating APACT pancreatic cancer trial in silico using RWD

Use case

Helping a biotech with drug combinations and indication expansion for a first-on-class inhibitor

Our platform empowers users to make the most of their data

Learn about Concr technology

Careers

Help us enable biopharma, diagnostics and healthcare industries to discover better ways to overcome cancer.

Career opportunities

Partnerships

Our partners leverage Concr advanced predictive modelling across every stage of therapeutic development to create shared value for the benefit of cancer patients.

Partnerships

Investors

Our growth is powered by funding and hands-on support from across three continents.

Investors and funding